drugset

drugset / Trial / NCT07505771

A Phase 1 Study of 177Lu-IM-3050 in Participants With Advanced Cancer

NCT07505771 ↗

Phase 0 Recruiting 105 enrolled Immunome, Inc.

Non-randomizedSequentialOpen-labelTreatment

Summary

IM-3050-101 is a Phase 1 study to determine the safety and effectiveness of 177Lu-IM-3050 in treating participants with advanced cancer.

Timeline

Start: 2026-06
Primary completion: 2029-12
Completion: 2034-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	177Lu-IM-3050	Unknown	—	Intravenous

Indications